Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma

Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma

Combined hepatocellular-cholangiocarcinoma (cHCC-ICC) is an uncommon and aggressive form of primary liver cancer. Currently, there are no international guidelines for optimal management. For localized tumors, radical resection represents the preferred treatment option, whereas for advanced tumors, s...

Full description

Bibliographic Details
Main Authors: Alexander A. Azizi, Andreas V. Hadjinicolaou, Carla Goncalves, Adam Duckworth, Bristi Basu
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Oncology
Subjects:
Combined hepatocellular-cholangiocarcinoma
cHCC-ICC
cHCC-CCA
biphenotypic
primary liver cancer
genomics
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.570958/full
Description
Summary:Combined hepatocellular-cholangiocarcinoma (cHCC-ICC) is an uncommon and aggressive form of primary liver cancer. Currently, there are no international guidelines for optimal management. For localized tumors, radical resection represents the preferred treatment option, whereas for advanced tumors, systemic therapies recommended for intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are often selected. Emerging information from comparative cohort studies, genomic and transcriptomic data sets are starting to build a case for rationalized approaches to systemic treatment in the advanced setting specific to cHCC-ICC.
ISSN:2234-943X

Similar Items